Media Coverage

Merck launches new vaccine to tackle PRRS


Sep 20, 2018 - Animal Pharm
By Daniel Willis

Merck Animal Health has launched its PRIME PAC PRRS RR vaccine with the intention to tackle porcine reproductive and respiratory syndrome (PRRS) virus.

PRIME PAC PRRS RR provides protection against respiratory and reproductive diseases causing by PRRS. The new vaccine will aid swine producers in protecting their herds from a disease that costs the US around $638 million in productivity losses each year. This makes PRRS one of the costliest animal diseases in the US, Merck claims.

Studies have shown the vaccine to be effective for the vaccination of healthy swine at three weeks of age or older against respiratory disease caused by the PRRS virus. The product has an immunity duration time of 20 weeks – saving swine producers time and money.

Brett O'Brien, a veterinarian in Merck's technical services division, said: "The dual protection against respiratory and reproductive disease of PRIME PAC PRRS RR is imperative to keep pigs healthy. Its convenient dosing of 1ml makes it easy for producers to implement in their disease-prevention protocols, and safe for the animal." 

Earlier this year, Elanco has joined the US market for PRRS vaccines after receiving approval for Prevacent PRRS. Zoetis sells Fostera PRRS in the US. This product is the only modified-live virus licensed for the vaccination of swine one day of age or older in the US. Fostera PRRS was granted licensure for whole-herd protection by the USDA.

Additionally, Boehringer Ingelheim Vetmedica markets Ingelvac PRRS MLV. This is also a modified-live vaccine, which can be used in pigs three weeks or older, gilts and sows at any stage of production. Boehringer also has the first combination vaccine for PRRS and Mycoplasma hyopneumoniae in its portfolio.

Last year, Aptimmune Biologics introduced the world's first mucosal vaccine for PRRS.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum